Midostaurin (Rydapt)

Midostaurin at a glance

Rydapt contains midostaurin, a medicine that blocks several proteins involved in abnormal cell growth. It is an oral kinase inhibitor, not an infusion or checkpoint immunotherapy. The reviewed product is a 25 mg soft capsule. Different treatment plans use different numbers of capsules and different days of treatment.

Take prescribed doses with food, usually about twelve hours apart. Anti-sickness medicine is normally prescribed to help prevent nausea and vomiting. Capsules must remain whole. A missed or vomited dose is skipped; it is not replaced with an extra dose.

Important concerns include low blood counts and infection, nausea and vomiting, lung inflammation, heart problems and medicine interactions. Monitoring remains necessary even when you feel well. Effects seen during chemotherapy combinations cannot all be attributed to midostaurin alone.

What midostaurin is and how it works

Kinases are proteins that help transmit instructions inside cells. Some abnormal cells depend on overactive kinase signals to grow and survive. Midostaurin blocks several of these proteins, including FLT3 and KIT. This can interfere with the growth of susceptible abnormal blood or mast cells.

FLT3 mutations are changes in a gene that can keep a growth signal switched on. KIT is another signalling protein relevant to mast cells, which are immune cells that release substances such as histamine. Midostaurin can affect abnormal KIT signalling as well as FLT3. These mechanisms do not mean that every condition involving these proteins will respond.

Treatment may combine medicines with different actions. Midostaurin does not replace prescribed chemotherapy simply because it is described as targeted. Your specialist assesses benefit through the disease-specific examination and test results, rather than through side effects or capsule dose alone.

How the team decides whether it is suitable

The specialist considers your precise diagnosis, laboratory and bone-marrow findings, previous treatment, general health and applicable prescribing information. When an acute myeloid leukaemia (AML) treatment plan is being considered, a validated test must confirm a relevant FLT3 mutation. Reports may describe FLT3-ITD (internal tandem duplication) or FLT3-TKD (tyrosine kinase domain mutation); these are different types of FLT3 change recognised in the prescribing information.

The testing approach for a mast-cell disorder differs. The team may examine KIT results alongside bone-marrow findings and evidence of organ involvement. A FLT3 test is not a universal entry requirement for every midostaurin treatment plan, and a particular KIT result should not be interpreted in isolation.

Tell the team about heart failure, an irregular heartbeat, fainting, lung disease, serious infection, liver or kidney problems and medicine allergies. A known allergy to midostaurin or its ingredients is a reason not to use Rydapt. Severe organ impairment requires particular caution because evidence is limited. Suitability for accompanying intensive chemotherapy is assessed separately.

This guide describes adult treatment. US safety and effectiveness in children are not established. Both labels highlight prolonged, severe blood-count suppression with certain intensive paediatric chemotherapy combinations; an adult plan must not be adapted for a child at home.

Before treatment starts

Blood tests assess blood-cell counts, liver and kidney function and electrolytes, including potassium and magnesium. Glucose and other chemistry tests help establish a baseline. The team checks existing symptoms so that changes during treatment can be assessed accurately.

Heart assessment may include an electrocardiogram, or ECG, which records electrical activity. An echocardiogram assesses pumping function when appropriate, particularly if there is a cardiac risk or accompanying treatment that can affect the heart. These tests answer different questions; a normal result does not remove the need to report symptoms later.

Tell the team about previous hepatitis or other significant infections. Viral screening and preventive anti-infective medicines depend on the overall treatment and your history. A serious active infection should be controlled before midostaurin is started alone. Do not assume everyone needs the same antiviral or antifungal prescription.

Bring all prescribed medicines, shop-bought products, supplements and herbal remedies for review. Discuss pregnancy prevention and fertility preservation before treatment where possible. If pregnancy is possible, the labels advise testing within seven days before starting.

Before leaving hospital, make sure you understand which days to take capsules, when to take anti-sickness medicine, when blood tests are due and how to contact your own urgent advice service. A written calendar is useful, especially when treatment changes from a combination phase to maintenance.

How treatment is taken

Follow the correct calendar

Each Rydapt capsule contains 25 mg. In a chemotherapy-cycle schedule, a usual example is 50 mg twice daily on days 8–21 of each induction or consolidation cycle. Induction is the initial phase intended to achieve remission; consolidation is further treatment to strengthen that response. That schedule means two capsules per dose during the specified days, not throughout every cycle. Your actual calendar takes priority.

European information also describes 50 mg twice daily every day as maintenance for patients in complete response, for up to twelve 28-day cycles or until relapse. Complete response means that the disease meets defined response criteria on assessment; it does not guarantee cure. The US dosing section does not provide that same maintenance recommendation. Do not start continuous dosing because a general information page mentions maintenance.

For a continuous mast-cell treatment plan, the usual starting example is 100 mg twice daily, meaning four capsules per dose, continued while beneficial and tolerable. A reduced dose may be prescribed for side effects. The two starting examples are not interchangeable.

Food, swallowing and sickness prevention

Take doses with food at about twelve-hour intervals, for example with breakfast and an evening meal. Swallow capsules whole with water. Do not chew, crush, open or dissolve them, or put their contents through a feeding tube. If swallowing becomes difficult, contact the pharmacist before the next dose for an individual plan.

Take the prescribed preventive anti-sickness medicine as instructed. If nausea continues, report it rather than abandoning food or repeatedly missing capsules. The team can review supportive treatment and, when necessary, hold or change midostaurin. Do not alter the dose yourself.

Missed doses, vomiting and storage

If you forget a dose, skip it and take the next scheduled dose at the usual time. If you vomit after taking a dose, do not take replacement capsules. Never double a dose to catch up. Record repeated missed or vomited doses and contact the team, because persistent problems need treatment.

If you take too much, or someone else takes your medicine, obtain urgent medical advice and take the pack with you. Keep capsules in their original packaging, protected from moisture and out of children's reach. US storage specifies 20–25°C (68–77°F); the European product has no special temperature requirement. Follow the dispensed pack's instructions and ask the pharmacist about excessive heat or damaged packaging. Return unused medicine for safe disposal.

Monitoring and checking whether treatment is working

Blood counts show whether infection-fighting white cells, oxygen-carrying red cells or platelets are falling. Liver and kidney tests, electrolytes and glucose may change before symptoms appear. Pancreatic enzymes and other tests are checked when appropriate to the treatment and findings.

Monitoring frequency depends on the regimen. For continuous mast-cell treatment, the US label specifies toxicity assessment at least weekly for the first four weeks, every other week for the next eight weeks, and monthly thereafter. This is not a substitute for the more intensive monitoring often needed during chemotherapy or an acute illness.

The team checks breathing and heart symptoms. Repeat ECGs are particularly relevant when other medicines can prolong the QT interval, an electrical recovery period of the heartbeat, or when electrolytes are abnormal. Heart-pumping tests are repeated when clinically indicated, rather than on one universal schedule.

Response checks may include blood and bone-marrow tests, symptoms, examinations and measures of affected organ function. The appropriate markers differ between treatment settings. A temporary pause or dose reduction can be a safety measure and does not by itself show that treatment has failed.

Common side effects and practical management

Nausea, vomiting and bowel changes

Nausea and vomiting are important midostaurin effects, which is why preventive medicine is prescribed. Small, manageable meals and frequent sips may help. Tell the team if you cannot eat enough to take capsules with food, or cannot keep liquids down.

Diarrhoea or constipation can occur. Record bowel changes and use only agreed medicines. Persistent diarrhoea can cause dehydration and disturb electrolytes, adding to heart-rhythm risk. Reduced urine, marked dizziness, fever, blood in stools or severe abdominal pain warrants prompt assessment. Respect any prescribed fluid restriction.

Constipation with increasing abdominal swelling, severe pain or vomiting also needs advice. Do not repeatedly increase laxatives without checking, particularly when blood counts are low or there is significant abdominal discomfort.

Blood-count changes, infection and bleeding

Low neutrophils, a type of white blood cell, reduce the body's ability to fight infection. Fever, chills, sore throat, a new cough, painful urination or redness around a catheter requires immediate contact with the team. Follow your hospital's temperature threshold; do not wait for a high fever if you suddenly feel very unwell.

Low platelets can cause bruising, small red or purple spots, nosebleeds or gum bleeding. Report new bleeding and check before using aspirin or anti-inflammatory painkillers. Black stools, vomiting blood or bleeding that will not stop needs emergency assessment.

Anaemia means too few red blood cells or too little haemoglobin. It can cause tiredness, breathlessness, dizziness or a racing heart. The team may arrange further tests or transfusion support. Do not assume worsening breathlessness is only anaemia, because lung and heart complications can look similar.

Mouth soreness, tiredness and discomfort

Mouth ulcers and soreness can make eating difficult, particularly with chemotherapy. Use gentle oral care and the rinses recommended by your team. Report white patches, increasing pain, inability to swallow or mouth symptoms with fever. Avoid experimenting with harsh mouthwashes.

Fatigue, headache, muscle or joint discomfort and disturbed sleep can occur. Pace activities, accept practical help and discuss suitable pain relief. A sudden severe headache, confusion, weakness or collapse should not be managed as an ordinary headache.

Skin changes and swelling

Rash, dry skin or peeling can occur. Use gentle skin care and report progression, pain or signs of infection. A widespread blistering rash or rash with facial swelling needs urgent assessment. Painful raised red or purple patches accompanied by fever can be a condition called Sweet syndrome and need prompt review.

Ankle or other swelling may develop. Record rapid weight changes and tell the team, especially if swelling occurs with cough or breathlessness. These symptoms may reflect fluid accumulation or a heart problem rather than a minor cosmetic change.

Important serious side effects

Lung inflammation

Midostaurin can cause inflammation within the lungs, called pneumonitis or interstitial lung disease. Serious and fatal cases have occurred with treatment alone and with chemotherapy. New or worsening cough, breathlessness, fever or chest discomfort needs immediate assessment. Infection and inflammation can produce similar symptoms and cannot reliably be distinguished at home.

The team may arrange oxygen checks, imaging and tests for infection. The US label directs discontinuation for signs or symptoms of pneumonitis or interstitial lung disease without an infectious cause. European guidance specifies discontinuation for severe non-infectious cases and also gives regimen-specific interruption rules. These differences do not justify waiting for breathing symptoms to become severe. Any restart requires an explicit specialist decision.

Heart rhythm and pumping problems

QT prolongation has been observed during treatment. Risk assessment includes other medicines and potassium or magnesium levels. A fast or irregular heartbeat, dizziness or fainting should be reported immediately; fainting with chest pain or severe breathlessness is an emergency.

Heart failure, reduced pumping function and fluid around the heart or lungs have also been reported. Warning symptoms include increasing breathlessness, difficulty breathing when lying down, leg swelling or rapid weight gain. Clinicians may hold treatment, adjust medicines and arrange ECG or heart imaging. Do not take an extra diuretic or stop heart medication without advice.

Changes in organ-function tests and eye symptoms

Liver tests, bilirubin, glucose, electrolytes or pancreatic enzymes can become abnormal. Report yellow eyes or skin, dark urine, marked thirst, unusually frequent urination or persistent severe abdominal pain. These symptoms need investigation; an abnormal pancreatic-enzyme result alone does not establish pancreatitis.

Eye inflammation has been reported in the chemotherapy treatment setting. A painful eye, blurred vision or unusual sensitivity to light needs prompt assessment. Avoid assuming that new visual symptoms are simply tiredness.

Other medicines, supplements and vaccinations

Midostaurin is broken down mainly through an enzyme called CYP3A4. Strong inhibitors can raise its level and increase toxicity. Examples include certain antifungals, such as posaconazole or voriconazole, some antibiotics and ritonavir-containing treatments. The labels recommend considering alternatives or close monitoring when an interacting medicine is necessary.

Antifungals may be essential during blood-cancer treatment. Do not stop one yourself because you recognise its name here. The specialist weighs infection prevention against interaction risk. Monitoring is particularly important when midostaurin starts or restarts, including the first week of dosing in a new chemotherapy cycle.

Strong enzyme inducers can reduce midostaurin exposure. These include rifampicin, carbamazepine, phenytoin and St John's wort. US guidance advises avoidance; European information lists strong CYP3A4 inducers as contraindicated. Do not start herbal mood remedies or change seizure treatment without a coordinated plan. Avoid grapefruit products unless your oncology pharmacist has specifically advised otherwise.

Midostaurin can also alter levels of other medicines, including bupropion and some statins. Anti-sickness medicines and other treatments may add to QT risk. Check every new medicine, including a short antibiotic course, with the oncology pharmacist. Separating doses by a few hours does not reliably remove these interactions.

Discuss vaccinations with the team. Avoid live vaccines while significantly immunosuppressed unless specifically authorised. Non-live vaccines may be suitable but can give less protection. Timing depends on chemotherapy, immune recovery and any transplant plan, rather than a single interval for everyone.

Everyday life during treatment

Plan meals around capsule times and ask for dietary help if nausea or mouth soreness limits intake. Keep a simple record of doses, symptoms and supportive medicines. This helps the team recognise a pattern and reduces the chance of duplicate doses when caregivers share responsibility.

Balance activity with rest. Avoid driving or operating machinery if dizzy, unsteady or unable to concentrate safely. Discuss work, travel and infection precautions in relation to blood counts and the treatment phase. Carry medicines in their original packs and plan refills before travelling.

Tell dentists, surgeons and other clinicians about midostaurin and accompanying medicines. Low counts or infection can affect the timing of procedures. There is no universal midostaurin surgical stopping interval in the reviewed labels; obtain an individual plan rather than stopping it yourself.

Rydapt contains a small amount of ethanol within the capsules. Mention alcohol-related concerns, epilepsy or liver disease to the pharmacist. This ingredient does not mean that drinking alcohol is automatically safe during treatment. Ask what is suitable for your overall regimen.

Fertility, contraception, pregnancy and breastfeeding

Midostaurin may harm a developing baby. Use effective contraception throughout treatment and for four months after the last dose if you could become pregnant; European wording specifies at least four months and a highly effective method, with a pregnancy rate below 1%. US guidance also specifies contraception for males with partners who could become pregnant throughout treatment and for four months afterwards.

Agree a reliable method with the team, taking account of other medicines and vomiting or diarrhoea that may affect oral contraception. Current European information does not anticipate reduced reliability of the studied ethinylestradiol/levonorgestrel combination from midostaurin itself; this should not be generalised to every hormonal method or accompanying drug. Report a suspected pregnancy promptly.

Do not breastfeed during treatment or for at least four months after the final dose. If chemotherapy or another medicine requires longer precautions, follow the longer agreed period.

Animal studies suggest potential effects on male and female fertility; human effects and reversibility are uncertain. Discuss sperm, egg or embryo preservation before treatment where feasible. Do not assume reduced fertility makes contraception unnecessary.

After treatment finishes

Continue agreed monitoring and report new symptoms after the final dose. Blood counts, organ function and treatment-related problems may need follow-up. Maintain contraception and breastfeeding restrictions for the full prescribed period.

If treatment is paused, obtain clear restart instructions. Do not use leftover capsules to restart an old schedule. If a stem-cell transplant is planned, the European label specifies stopping midostaurin 48 hours before the conditioning regimen; the transplant team must organise the timing. This is not a general rule for every operation or hospital admission.

Ask which tests will assess disease control, which supportive medicines should continue and what changes need urgent contact. Return unused capsules through the pharmacy and keep a treatment summary for other healthcare professionals.

Frequently asked questions